From: the 2014 ASCO GU Meeting
Abstract No: 35
Researchers have found in a randomized controlled trial of men with metastatic castration-resistant prostate cancer (mCRPC) the use of the treatment denosumab was superior to the more commonly used zoledronic acid (ZA) for reducing skeletal-related events (SRE). SREs are defined as a pathological fracture, surgery or radiation to the bone [including the use of radioisotopes], or spinal cord compression.
In the trial men with mCRPC who had at least one or more SRE and never received IV bisphosphonate were randomized to receive either denosumab 120 mg or IV ZA 4 mg (adjusted for creatinine clearance) every 4 weeks. Oral calcium and vitamin D supplements were also recommended.
This trial confirmed the previously reported result from other studies that fewer men who received denosumab than ZA had confirmed first SREs as well as additional multiple SREs.
The median (95% CI) estimate of time to first SSE for den